BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761]
URL: https://www.wjgnet.com/1948-5182/full/v11/i12/761.htm
Number Citing Articles
1
Tanvi Patel, Kimberly McBennett, Senthilkumar Sankararaman, Teresa Schindler, Krithika Sundaram, Nori Mercuri Minich, Sindhoosha Malay, Katherine Kutney. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat‐soluble vitamin levels and association with body mass indexPediatric Pulmonology 2024; 59(3): 734 doi: 10.1002/ppul.26823
2
Rosara Bass, Jessica A. Alvarez. Nutritional status in the era of highly effective CFTR modulatorsPediatric Pulmonology 2024; 59(S1) doi: 10.1002/ppul.26806
3
Julia Konrad, Ernst Eber, Vanessa Stadlbauer. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulatorsPaediatric Respiratory Reviews 2022; 42: 9 doi: 10.1016/j.prrv.2020.12.001
4
Lucile Regard, Clémence Martin, Jennifer Da Silva, Pierre-Régis Burgel. CFTR Modulators: Current Status and Evolving KnowledgeSeminars in Respiratory and Critical Care Medicine 2023; 44(02): 186 doi: 10.1055/s-0042-1758851
5
Aikaterini Kanavaki, Ino Kanavaki, Pavlos S. Zoumpoulis, Maria Moustaki, Konstantinos Douros, Ioanna Loukou. Changes in Shear Wave Elastography after Lumacaftor/Ivacaftor Treatment in Children with Cystic FibrosisCurrent Drug Safety 2023; 18(1): 93 doi: 10.2174/1574886317666220513105114
6
Kimberly McBennett, Christina J. MacAskill, Elise Keshock, Maryam Ghadimi Mahani, Jaime Mata, Alexander J. Towbin, Senthilkumar Sankararaman, Mitchell L. Drumm, Xin Yu, Clement L. Ren, Samya Z. Nasr, Katherine Kutney, Chris A. Flask. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapiesJournal of Cystic Fibrosis 2022; 21(2): e148 doi: 10.1016/j.jcf.2021.11.006
7
Adrienne P. Savant, Susanna A. McColley. Cystic fibrosis year in review 2019: Section 1 CFTR modulatorsPediatric Pulmonology 2020; 55(12): 3236 doi: 10.1002/ppul.25039
8
Zachary M. Sellers, David N. Assis, Shruti M. Paranjape, Meghana Sathe, Frank Bodewes, Melissa Bowen, Marco Cipolli, Dominique Debray, Nicole Green, Kara S. Hughan, William R. Hunt, Julio Leey, Simon C. Ling, Giuseppe Morelli, Daniel Peckham, Rebeca S. Pettit, Alexander Philbrick, Janis Stoll, Kay Vavrina, Stacy Allen, Tara Goodwin, Sarah E. Hempstead, Michael R. Narkewicz. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendationsHepatology 2023;  doi: 10.1097/HEP.0000000000000646
9
Mitchell L Ramsey, Michael R Wellner, Kyle Porter, Stephen E Kirkby, Susan S Li, Luis F Lara, Sean G Kelly, A James Hanje, Lindsay A Sobotka. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosisWorld Journal of Hepatology 2022; 14(2): 411-419 doi: 10.4254/wjh.v14.i2.411
10
Theresa Frantzen, Sara Barsky, Geralyn LaVecchia, Michelle Marowitz, Janice Wang. Evolving Nutritional Needs in Cystic FibrosisLife 2023; 13(7): 1431 doi: 10.3390/life13071431
11
Patience Eschenhagen, Carsten Schwarz. Viele Patienten mit Mukoviszidose haben jetzt eine bessere LebensqualitätMMW - Fortschritte der Medizin 2021; 163(S1): 74 doi: 10.1007/s15006-021-9804-z
12
Pawel E. Ferdek, Daria Krzysztofik, Kinga B. Stopa, Agnieszka A. Kusiak, Milena Paw, Dawid Wnuk, Monika A. Jakubowska. When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosisThe Journal of Physiology 2022; 600(11): 2579 doi: 10.1113/JP281135
13
Almudena Marinero Martínez-Lázaro, Rosa María Girón Moreno, Fernando Casals Seoane, Óscar Cano-Valderrama, Luisa García-Buey. Cystic fibrosis with liver involvement in adults has a benign course. Results from a tertiary referral centre cohortRevista Española de Enfermedades Digestivas 2022; 114 doi: 10.17235/reed.2022.9289/2022
14
Dana-Teodora Anton-Păduraru, Alice Nicoleta Azoicăi, Felicia Trofin, Alina Mariela Murgu, Dana Elena Mîndru, Ana Simona Bocec, Codruța Olimpiada Iliescu Halițchi, Gabriela Rusu Zota, Diana Păduraru, Eduard Vasile Nastase. Diagnosis, Management, and Prognosis of Cystic Fibrosis-Related Liver Disease in ChildrenDiagnostics 2024; 14(5): 538 doi: 10.3390/diagnostics14050538
15
Robert D. Baker, Susan S. Baker. Cystic Fibrosis‐related Liver DiseaseJournal of Pediatric Gastroenterology and Nutrition 2020; 71(4): 421 doi: 10.1097/MPG.0000000000002867
16
Leonardo Pozo, Fatimah Bello, Yamely Mendez, Salim Surani. Cystic fibrosis-related diabetes: The unmet needWorld Journal of Diabetes 2020; 11(6): 213-217 doi: 10.4239/wjd.v11.i6.213
17
Daniel B. Karb, Linda C. Cummings. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic FibrosisCurrent Gastroenterology Reports 2021; 23(10) doi: 10.1007/s11894-021-00817-2
18
Katherine A. Despotes, Scott H. Donaldson. Current state of CFTR modulators for treatment of Cystic FibrosisCurrent Opinion in Pharmacology 2022; 65: 102239 doi: 10.1016/j.coph.2022.102239
19
Jonathan E. M. O'Donnell, Lucy A. Hastings, Julie N. Briody, Christine L. Chan, Carla Colombo, Tonia A. Douglas, Steven D. Freedman, Tanja Gonska, Jerry R. Greenfield, Daniel H. Leung, Adeline Y. L. Lim, Antoinette Moran, Bernadette J. Prentice, Melissa S. Putman, Michael Trotter, Elizabeth Tullis, Glen P. Westall, Charles F. Verge, Claire E. Wainwright, Chee Y. Ooi. SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) SymposiumPediatric Pulmonology 2024; 59(6): 1661 doi: 10.1002/ppul.26970
20
Katharina Staufer. Current Treatment Options for Cystic Fibrosis-Related Liver DiseaseInternational Journal of Molecular Sciences 2020; 21(22): 8586 doi: 10.3390/ijms21228586
21
Alexander J. Towbin, Wen Ye, Suiyuan Huang, Boaz W. Karmazyn, Jean P. Molleston, Prakash Masand, Daniel H. Leung, Samuel Chang, Michael R. Narkewicz, Adina L. Alazraki, A. Jay Freeman, Randolph K. Otto, Nicole Green, Ihab R. Kamel, Wikrom W. Karnsakul, John C. Magee, Jean Tkach, Joseph J. Palermo. Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasoundPediatric Radiology 2023; 53(11): 2210 doi: 10.1007/s00247-023-05706-6
22
Marie‐Ève Bolduc, Kathryn J. Potter, Maxime Olmos, Anne Bonhoure, Adèle Coriati, Laure Alexandre‐Heymann, François Tremblay, Annick Lavoie, Maité Carricart, Peter A. Senior, Valérie Boudreau, Rémi Rabasa‐Lhoret. Cystic fibrosis‐related diabetes develops from a combination of insulin secretion defects and insulin resistanceDiabetes, Obesity and Metabolism 2024; 26(10): 4744 doi: 10.1111/dom.15844
23
Jordan S. Sherwood, Jagdeesh Ullal, Katherine Kutney, Kara S. Hughan. Cystic fibrosis related liver disease and endocrine considerationsJournal of Clinical & Translational Endocrinology 2022; 27: 100283 doi: 10.1016/j.jcte.2021.100283
24
Jérémy Dana, Dominique Debray, Aurélie Beaufrère, Sophie Hillaire, Monique Fabre, Caroline Reinhold, Thomas F. Baumert, Laureline Berteloot, Valérie Vilgrain. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapiesJournal of Hepatology 2022; 76(2): 420 doi: 10.1016/j.jhep.2021.09.042
25
Michael R. Narkewicz. Cystic fibrosis liver disease in the post-modulator eraCurrent Opinion in Pulmonary Medicine 2023; 29(6): 621 doi: 10.1097/MCP.0000000000001017
26
Varinder S. Athwal, Jennifer A. Scott, Emer Fitzpatrick, Marion Rowland. Emerging clinical perspectives in cystic fibrosis liver diseaseCurrent Opinion in Pulmonary Medicine 2021; 27(6): 593 doi: 10.1097/MCP.0000000000000824
27
I.M. Balfour-Lynn, J.A. King. CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosisPaediatric Respiratory Reviews 2022; 42: 3 doi: 10.1016/j.prrv.2020.05.002
28
Jessica A. Eldredge, Mark R. Oliver, Chee Y. Ooi. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulatorsPaediatric Respiratory Reviews 2024; 50: 54 doi: 10.1016/j.prrv.2023.12.005
29
Keyan Zarei, Mallory R. Stroik, Nick D. Gansemer, Andrew L. Thurman, Lynda S. Ostedgaard, Sarah E. Ernst, Ian M. Thornell, Linda S. Powers, Alejandro A. Pezzulo, David K. Meyerholz, David A. Stoltz. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine modelLaboratory Investigation 2020; 100(11): 1388 doi: 10.1038/s41374-020-0474-8
30
A. G. Chermensky, T. E. Gembitskaya, A. V. Orlov, V. R. Makhmutova. The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosisMeditsinskiy sovet = Medical Council 2022; (4): 98 doi: 10.21518/2079-701X-2022-16-4-98-106
31
Murali K. Yanda, Adi Zeidan, Liudmila Cebotaru. Ameliorating liver disease in an autosomal recessive polycystic kidney disease mouse modelAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2023; 324(5): G404 doi: 10.1152/ajpgi.00255.2022
32
Frank A.J.A. Bodewes, Alvin Jay Freeman, Alexander Weymann, Dominique Debray, Isabelle Scheers, Henkjan J. Verkade, Michael R. Narkewicz. Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position PaperJournal of Pediatric Gastroenterology and Nutrition 2024; 78(1): 153 doi: 10.1097/MPG.0000000000003944
33
Joseph J Valamparampil, Girish L Gupte. Cystic fibrosis associated liver disease in childrenWorld Journal of Hepatology 2021; 13(11): 1727-1742 doi: 10.4254/wjh.v13.i11.1727
34
David Drummond, Jérémy Dana, Laureline Berteloot, Elena K. Schneider-Futschik, Frédérique Chedevergne, Céline Bailly-Botuha, Thao Nguyen-Khoa, Mathieu Cornet, Muriel Le Bourgeois, Dominique Debray, Muriel Girard, Isabelle Sermet-Gaudelus. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTRJournal of Cystic Fibrosis 2022; 21(2): 212 doi: 10.1016/j.jcf.2021.07.018